Skip to main content
. 2020 Feb 6;10(2):e030114. doi: 10.1136/bmjopen-2019-030114

Table 4.

Drug-related adverse events

Orvepitant 30 mg
n=16
n (%)
Orvepitant 10 mg
n=14
n (%)
Placebo
n=14
n (%)
Any drug-related AE 3 (18.8) 1 (7.1) 0
Mild AEs
 Asthenia 1 (6.3) 0 0
 Dizziness 0 1 (7.1) 0
 Dry mouth 1 (6.3) 0 0
Moderate AEs
 Hyperhidrosis 1 (6.3) 0 0

AE, adverse event.